Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2017-08-10 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a press release announcing preliminary clinical trial results for a drug candidate, KP415. There are no financial statements or detailed financial performance data included. The document primarily serves as a disclosure of a specific event (clinical trial results) rather than a financial report or management discussion. It also includes a cautionary forward-looking statement typical of press releases and current reports. Given the nature of the content and the form type, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-08-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 28, 2017. It announces a press release about advances in the company's ADHD prodrug pipeline and a conference call with a slide presentation. The document includes a Regulation FD Disclosure and references exhibits containing a press release and a presentation. The content is primarily an announcement of events and disclosures rather than a full financial report or detailed financial statements. The document length is 7,380 characters, which is relatively short and consistent with an announcement rather than a full report. The presence of a conference call and slide presentation suggests investor communication but not a full investor presentation document. The document does not contain detailed financial data or analysis, so it is not an Interim/Quarterly Report or Annual Report. It is not a certification or legal proceeding. The document is best classified as a Regulatory Filing (RNS) because it is a current report filing announcing material events and disclosures without constituting a full financial report or other specific filing type.
2017-06-28 English
FORM 4
Director's Dealing
2017-06-21 English
FORM 4
Director's Dealing
2017-06-21 English
FORM 4
Director's Dealing
2017-05-26 English
FORM 4
Director's Dealing
2017-05-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.